Agilent Technologies

Podcasts

Minimize Compliance Risk using Agilent CrossLab Compliance Services

Why Access to Instrument Utilization Data is Critical for Optimizing the Laboratory

Advance Your Lab Operations with Agilent’s CrossLab Enterprise Services

http://www.spectroscopyonline.com/spec_w/pharmaceutical

	There is no room for delays in your pharmaceutical analysis, but certainty is critical.  This webcast will describe new technologies that can dramatically reduce the risks around routine analysis while also reducing the time required from hours and days to minutes.  First you will learn about the use of Raman technologies for improving the speed and efficiency of pharmaceutical testing, including through-container raw material identification, and non-destructive tablet or capsule polymorph analysis and content uniformity in batch release.  The second presentation will discuss a new molecular spectroscopy technology that is making sensitive quantitation of crystallinity and high-quality surface imaging of entire tablets possible in just a few minutes.  We will also present a new UV/Vis technology that allows you to simultaneously measure standards and unknown samples across eight cuvette positions in a single experiment providing both efficiency gains and utmost data quality.

			How raw material ID verification through opaque barriers enables high-throughput ID testing for incoming containers, lowering costs and streamlining the QC workflow

			The benefits of transmission Raman spectroscopy for content uniformity testing, and how it works in conjunction with established HPLC methods to increase throughput and reduce costs

			New LDIR technology for analysis of different polymorph forms in solid oral dose tablets

			How simultaneous UV/Vis measurements can remove data quality risks while increasing efficiency of analysis

Darren Andrews Ph.D., Head of Pharma Business, Raman Spectroscopy, Agilent Technologies

	Ursula Tems, Ph.D., Product Manager, Molecular Spectroscopy, Agilent Technologies

 Europe: Wednesday, Oct.16, 2019 at 9am EDT | 2pm BST | 3pm CEST

	US: Wednesday, Oct. 16, 2019 at 2pm EDT | 1pm CDT| 11am PDT

	On demand available after airing until Oct. 16, 2020.

Webcasts

Join us for this webcast to learn about new technologies that can dramatically reduce the risks around routine pharmaceutical analysis while also reducing the time required from hours and days to minutes.
Live: Europe: Wednesday, Oct. 16, 2019 at 9am EDT | 2pm BST | 3pm CEST
US: Wednesday, Oct. 16, 2019 at 2pm EDT | 1pm CDT| 11am PDT
On demand available after final airing until Oct. 16, 2020
Register free

Workflow Breakthroughs that Are Improving Data Quality and Efficiency and Changing Pharmaceutical Analysis

	Sayuri Otaki, ICP-MS marketing manager, Agilent Technologies

	ICP-MS provides accurate, multielement analysis with low detection limits. However, real-world performance is strongly affected by the instrument configuration and operating conditions. The following parameters should be considered when evaluating ICP-MS capability for your laboratory and application.

Consider the number and type of the samples that will be analyzed

		The number of samples per day will influence the required instrument configuration. Large-capacity autosamplers are available to allow long sequences of samples to be run unattended.

		For the highest productivity, a discrete sampling device such as the Agilent Integrated Sample Introduction System (ISIS) can reduce the sample-to-sample time to less than 60 seconds.

		High matrix samples may require dilution, using a liquid autodilutor or aerosol dilution, for example using the high matrix introduction (HMI) technology available on Agilent ICP-MS systems.

		Many regulated methods include several analytes that benefit from the addition of 0.5%-1.0% chloride (as HCl) to ensure their chemical stability. Affected elements include Hg, As, Se, Mo, Tl and Ag.

		Adding HCl causes Cl-based interferences on elements including V, Cr, and As. These and other polyatomic interferences can be controlled using helium (He) collision mode, using an octopole-based cell.

		Analysis of long sequences of high matrix samples requires good plasma robustness to ensure that matrix deposition does not compromise stability. Poor plasma robustness increases matrix deposition on the interface cones, which leads to signal drift, QC failures, and degraded detection limits.

		Plasma robustness is measured using the cerium oxide ratio (CeO

). A lower ratio-around 1.0% to 1.5% is typical for Agilent ICP-MS systems-indicates a more robust plasma.


	Figure 1: Excellent stability of internal standard signals throughout sample sequence of varied saline samples. Each sample was measured in triplicate using the Agilent 7800 ICP-MS with ISIS discrete sampling and HMI aerosol dilution. He cell gas mode only. ISTDs added online at 1:1 ratio. See reference 1.

	Confirm the instrument meets your method requirements

		Analytical methods usually have defined requirements for performance indicators such as detection limits, linearity, spike recovery, bias, and drift. Confirm the instrument you are considering meets your analytical requirements, and that you are aware of the method setup needed to achieve this performance.

		Make sure you understand which cell gas modes are required. Most common applications can be run using only He mode, making methods more universal and reliable than if reaction gases are required.

	Evaluate performance for your real application and samples

		An ICP-MS represents a big investment, so it is essential that you do a full evaluation to ensure you select the instrument that best meets your needs. Observing routine sample analysis under similar conditions to your routine workflow will give you a good indication of true instrument capability.

		It is always better to test instrument performance for your typical or most difficult sample types, not just evaluate performance running simple, synthetic standards.

	(1) "High Throughput, Direct Analysis of Seawater using the Agilent 7800 ICP-MS with HMI for Aerosol Dilution," Agilent, 5991-7936EN (2017).

Agilent Technologies

Articles

Minimize Compliance Risk using Agilent CrossLab Compliance Services

Why Access to Instrument Utilization Data is Critical for Optimizing the Laboratory

Advance Your Lab Operations with Agilent’s CrossLab Enterprise Services

Workflow Breakthroughs that Are Improving Data Quality and Efficiency and Changing Pharmaceutical Analysis

Parameters to Consider When Evaluating ICP-MS Configurations and Performance